Ticker > Company >

Samrat Pharmachem share price

Samrat Pharmachem Ltd.

BSE: 530125 SECTOR: Pharmaceuticals & Drugs  20k   136   14

466.00
-20.80 (-4.27%)
BSE: Today, 11:53 AM

Price Summary

Today's High

₹ 499

Today's Low

₹ 462.5

52 Week High

₹ 646

52 Week Low

₹ 320

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

143.98 Cr.

Enterprise Value

142.71 Cr.

No. of Shares

0.31 Cr.

P/E

39.82

P/B

2.15

Face Value

₹ 10

Div. Yield

0.21 %

Book Value (TTM)

₹  217.05

CASH

9.73 Cr.

DEBT

8.45 Cr.

Promoter Holding

48.95 %

EPS (TTM)

₹  11.7

Sales Growth

-9.36%

ROE

3.38 %

ROCE

4.13%

Profit Growth

-87 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-9.36%
3 Year16.3%
5 Year20.43%

Profit Growth

1 Year-87%
3 Year-25.98%
5 Year7.09%

ROE%

1 Year3.38%
3 Year26.19%
5 Year23.49%

ROCE %

1 Year4.13%
3 Year30.46%
5 Year27.54%

Debt/Equity

0.1301

Price to Cash Flow

15.3

Interest Cover Ratio

4.6684

CFO/PAT (5 Yr. Avg.)

0.459319151535634

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2024 48.95 0.00
Jun 2024 48.64 0.00
Mar 2024 48.64 0.00
Dec 2023 48.64 0.00
Sep 2023 48.64 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good revenue growth of 16.2969944005669% for the Past 3 years.
  • The company has significantly decreased its debt by 10.2046 Cr.
  • The company has an efficient Cash Conversion Cycle of 59.1702 days.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 5.60006533457187.

 Limitations

  • The company has shown a poor profit growth of -25.9833469764689% for the Past 3 years.
  • Tax rate is low at 14.1894.
  • The company is trading at a high PE of 39.82.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024
Net Sales 57.48 79.75 61.67 82.68 80.82
Total Expenditure 56.71 79.51 61.56 81.33 78.24
Operating Profit 0.77 0.23 0.11 1.36 2.58
Other Income 0.36 0.3 0.42 0.3 0.59
Interest 0.22 0.13 0.23 0.11 0.19
Depreciation 0.16 0.16 0.16 0.16 0.16
Exceptional Items 0 0 0 0 0
Profit Before Tax 0.75 0.24 0.14 1.39 2.82
Tax 0.14 0.43 -0.2 -0.01 0.75
Profit After Tax 0.61 -0.19 0.34 1.4 2.07
Adjusted EPS (Rs) 1.98 -0.61 1.11 4.51 6.68

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 137.45 179.02 221.75 310.65 281.58
Total Expenditure 130.82 170.35 197.51 286.72 279.11
Operating Profit 6.63 8.67 24.24 23.93 2.47
Other Income 0.57 0.46 0.63 0.48 1.38
Interest 0.98 1.28 0.67 1.23 0.69
Depreciation 0.43 0.49 0.59 0.64 0.65
Exceptional Items -0.01 -0.02 0 0 0
Profit Before Tax 5.78 7.34 23.6 22.53 2.52
Tax 1.55 2.01 6.42 5.9 0.36
Net Profit 4.24 5.33 17.18 16.63 2.16
Adjusted EPS (Rs.) 13.71 17.26 55.62 53.83 7

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 3.09 3.09 3.09 3.09 3.09
Total Reserves 21.21 26.55 43.73 60.05 61.91
Borrowings 0 0 0 0 0
Other N/C liabilities 0.14 0.43 0.46 0.25 0.34
Current liabilities 33.9 27.33 37.33 53.19 56.4
Total Liabilities 58.35 57.4 84.61 116.59 121.74
Assets
Net Block 7.19 9.4 9.99 10.7 10.72
Capital WIP 1.08 0 0 0 0
Intangible WIP 0 0 0 0 0
Investments 0 0 0 1.86 2.92
Loans & Advances 0.4 0.65 0.8 0.91 1.47
Other N/C Assets 0 0.02 2.56 4.06 4.06
Current Assets 49.68 47.32 71.26 99.05 102.57
Total Assets 58.35 57.4 84.61 116.59 121.74
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 5.79 7.34 23.6 22.53 2.52
Adjustment 1.39 1.7 1.19 1.65 0.03
Changes in Assets & Liabilities -7.62 -1.99 -5.78 -24.12 9.27
Tax Paid -0.87 -2.25 -1.53 -9.5 -2.41
Operating Cash Flow -1.33 4.8 17.47 -9.44 9.41
Investing Cash Flow -1.92 -2.92 -1.06 -3 -0.41
Financing Cash Flow 2 -1.89 -1.95 9.6 -11.2
Net Cash Flow -1.25 -0.02 14.46 -2.84 -2.19

Corporate Actions

Investors Details

PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
promoters 48.64 48.64 48.64 48.64 48.95
falguni kaushal mehta 2.15 2.15 2.15 2.15 2.15
jaya lalit mehta 3.86 3.86 3.86 3.86 3.86
kalpana premal mehta 1.64 1.64 1.64 1.64 1.64
kaushal lalit mehta 4.50 4.50 4.50 4.50 4.50
lalit damodar mehta 13.97 13.97 13.97 13.97 13.97
maitri megh mehta 0.27 0.27 0.27 0.27 0.38
megh rajesh mehta 1.51 1.51 1.51 1.51 1.71
premal lalit mehta 5.67 5.67 5.67 5.67 5.67
rajesh lalit mehta 12.41 12.41 12.41 12.41 12.41
rupal rajesh mehta 2.66 2.66 2.66 2.66 2.66
PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
investors 51.36 51.36 51.36 51.36 51.05
anshul specialty molecule... 1.31 1.31 1.31 1.31 1.31
lalit kumar v jain - - - - 1.09
lloyds securities oversea... 3.24 3.24 3.24 3.24 3.24
llp 0.03 0.03 0.03 0.04 0.05
sangeetha s 3.27 3.27 3.27 3.27 3.27
sharad kanayalal shah 1.13 1.13 1.13 1.13 1.13

Ratings & Research Reports

Company Presentations

Currently we do not have any Presentation and Concall related to this company.Report us

Company News

Samrat Pharmachem informs about newspaper publication 23 Aug, 4:12 PM Samrat Pharmachem - Quaterly Results 13 Aug, 5:16 PM Samrat Pharmachem - Quaterly Results 13 Aug, 5:16 PM Samrat Pharmachem informs about newspaper advertisement 3 Jun, 5:29 PM Samrat Pharmachem - Quaterly Results 14 Feb, 4:06 PM Samrat Pharmachem - Quaterly Results 14 Feb, 4:06 PM Samrat Pharmachem informs about newspapers advertisement 23 Nov, 5:20 PM Samrat Pharmachem informs about press release 18 Sep, 5:08 PM Samrat Pharmachem informs about record date for dividend payment 8 Sep, 5:16 PM Samrat Pharmachem - Quaterly Results 14 Aug, 3:57 PM Samrat Pharmachem informs about loss of share certificates 9 Aug, 3:14 PM Samrat Pharmachem informs about issuance of duplicate share certificates 24 Jul, 5:12 PM Samrat Pharmachem informs about issuance of duplicate share certificate 22 May, 12:32 PM Samrat Pharmachem informs about non-applicability of large corporate entity 10 May, 3:07 PM Samrat Pharmachem informs about certificate 12 Apr, 4:05 PM Samrat Pharmachem informs about issuance of duplicate share certificate 3 Apr, 4:46 PM Samrat Pharmachem informs about trading window closure 28 Mar, 4:47 PM Samrat Pharmachem informs about loss of share certificate 24 Mar, 4:38 PM Samrat Pharmachem informs about issuance of duplicate certificate 30 Jan, 5:23 PM Samrat Pharmachem - Quaterly Results 14 Nov, 3:32 PM Samrat Pharmachem informs about compliance certificate 12 Oct, 5:11 PM Samrat Pharmachem informs about outcome of AGM 3 Oct, 4:54 PM Samrat Pharmachem informs about approval of un-audited financial results 10 Feb, 5:00 PM Samrat Pharmachem - Quaterly Results 10 Feb, 3:41 PM Samrat Pharmachem - Quaterly Results 10 Feb, 3:41 PM Samrat Pharmachem - Quaterly Results 10 Feb, 3:41 PM Samrat Pharmachem informs about newspaper publication 19 Nov, 1:37 PM Samrat Pharmachem informs about newspaper advertisement 17 Feb, 4:20 PM Samrat Pharmachem informs about newspaper publication 24 Dec, 3:15 PM

Samrat Pharmachem Stock Price Analysis and Quick Research Report. Is Samrat Pharmachem an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Samrat Pharmachem and its performance over the period of time. Samrat Pharmachem stock price today is Rs 466.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Samrat Pharmachem cash from the operating activity was Rs 9.412 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Samrat Pharmachem has a Debt to Equity ratio of 0.1301 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Samrat Pharmachem , the EPS growth was -86.9962 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Samrat Pharmachem has OPM of 0.877011675495375 % which is a bad sign for profitability.
     
  • ROE: Samrat Pharmachem have a poor ROE of 3.3754 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Samrat Pharmachem is Rs 466. One can use valuation calculators of ticker to know if Samrat Pharmachem share price is undervalued or overvalued.
Last Updated on:
Brief about Samrat Pharmachem
X